Immunohistochemical Antibody Panel for the Differential Diagnosis of Pancreatic Ductal Carcinoma From Gastrointestinal Contamination and Benign Pancreatic Duct Epithelium in Endoscopic Ultrasound-Guided Fine-Needle Aspiration
Authors:
- Sachiko MinamiguchiSMSachiko Minamiguchi
- Hiroyuki ShirahaseHSHiroyuki Shirahase
- Yuzo KodamaYKYuzo Kodama
- Souichi AdachiSASouichi Adachi
- Takaki SakuraiTSTakaki Sakurai
- Hironori HagaHHHironori Haga
- 1 April 2017
- journal article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 46 (4) , 531-538
Abstract
The diagnosis of pancreatic ductal adenocarcinoma (PDAC) by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) can be challenging to distinguish tumor cells from benign epithelium (BE). The aim of the present study was to set a minimal antibody panel to differentiate PDAC from contaminated BE in EUS-FNA specimens. Immunohistochemistry using claudin 4, EZH2, Ki-67, maspin, p53, and S100P was performed on tissue microarray sections containing 53 PDACs and 33 BE as well as cell blocks of EUS-FNA including 53 PDACs and 22 BE. The positive rate was scored as 0 to 4+. The receiver operating characteristic curve was applied to determine a cutoff point, and the Classification And Regression Trees method was used to obtain a classification tree of the best panel. The cutoff point was 1+ for claudin 4, EZH2, Ki-67, p53, and S100P and 2+ for maspin. All BE scored 0 for p53. The classification tree revealed using p53, S100P, and claudin 4 was the most powerful. The sensitivity and specificity of the tree were 96.2% and 100% in tissue microarrays and 100% and 95.5% in EUS-FNA, respectively. The classification tree using p53, S100P, and claudin 4 seems to successfully distinguish PDAC from the accompanying BE.Keywords
This publication has 25 references indexed in Scilit:
- Neoadjuvant Therapy in Pancreatic Cancer: An Emerging StrategyGastroenterology Research and Practice, 2014
- Immunostaining for Polycomb Group Protein EZH2 and Senescent Marker p16INK4a May Be Useful to Differentiate Cholangiolocellular Carcinoma From Ductular Reaction and Bile Duct AdenomaAmerican Journal of Surgical Pathology, 2014
- Influence of the safety and diagnostic accuracy of preoperative endoscopic ultrasound-guided fine-needle aspiration for resectable pancreatic cancer on clinical performanceWorld Journal of Gastroenterology, 2014
- Usefulness of Brush Cytology Combined With Pancreatic Juice Cytology in the Diagnosis of Pancreatic CancerPancreas, 2012
- Diagnostic ability and factors affecting accuracy of endoscopic ultrasound-guided fine needle aspiration for pancreatic solid lesions: Japanese large single center experienceJournal of Gastroenterology, 2012
- Foamy gland pancreatic ductal adenocarcinoma diagnosed on EUS‐FNA: A histochemical, immunohistochemical, and molecular reportDiagnostic Cytopathology, 2012
- Reevaluation and Identification of the Best Immunohistochemical Panel (pVHL, Maspin, S100P, IMP-3) for Ductal Adenocarcinoma of the PancreasArchives of Pathology & Laboratory Medicine, 2012
- The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14‐3‐3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine‐needle aspirationDiagnostic Cytopathology, 2011
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLOS Medicine, 2010
- Staining for p53 and Ki-67 increases the sensitivity of EUS-FNA to detect pancreatic malignancyWorld Journal of Gastrointestinal Endoscopy, 2010